These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2627754)

  • 41. Aldosterone-specific membrane receptors and related rapid, non-genomic effects.
    Wehling M; Christ M; Gerzer R
    Trends Pharmacol Sci; 1993 Jan; 14(1):1-4. PubMed ID: 8382884
    [No Abstract]   [Full Text] [Related]  

  • 42. Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1.
    Riepe FG; Finkeldei J; de Sanctis L; Einaudi S; Testa A; Karges B; Peter M; Viemann M; Grötzinger J; Sippell WG; Fejes-Toth G; Krone N
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4552-61. PubMed ID: 16954160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pseudohypoaldosteronism.
    Dillon MJ; Leonard JV; Buckler JM; Ogilvie D; Lillystone D; Honour JW; Shackleton CH
    Arch Dis Child; 1980 Jun; 55(6):427-34. PubMed ID: 7002056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generalized unresponsiveness to mineralocorticoid hormones: familial recessive pseudohypoaldosteronism due to aldosterone-receptor deficiency.
    Bosson D; Kuhnle U; Mees N; Ramet J; Vamos E; Vertongen F; Wolter R; Armanini D
    Acta Endocrinol Suppl (Copenh); 1986; 279():376-80. PubMed ID: 2946135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of a novel mutation in the human mineralocorticoid receptor gene in a german family with autosomal-dominant pseudohypoaldosteronism type 1: further evidence for marked interindividual clinical heterogeneity.
    Riepe FG; Krone N; Morlot M; Ludwig M; Sippell WG; Partsch CJ
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1683-6. PubMed ID: 12679457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adult nephron-specific MR-deficient mice develop a severe renal PHA-1 phenotype.
    Canonica J; Sergi C; Maillard M; Klusonova P; Odermatt A; Koesters R; Loffing-Cueni D; Loffing J; Rossier B; Frateschi S; Hummler E
    Pflugers Arch; 2016 May; 468(5):895-908. PubMed ID: 26762397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte excretion: toward a redefinition of mineralocorticoid action.
    Funder JW; Pearce PT; Myles K; Roy LP
    FASEB J; 1990 Nov; 4(14):3234-8. PubMed ID: 2172062
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1.
    Fernandes-Rosa FL; Hubert EL; Fagart J; Tchitchek N; Gomes D; Jouanno E; Benecke A; Rafestin-Oblin ME; Jeunemaitre X; Antonini SR; Zennaro MC
    J Clin Endocrinol Metab; 2011 Mar; 96(3):E519-27. PubMed ID: 21159846
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aldosterone-specific membrane receptors and rapid non-genomic actions of mineralocorticoids.
    Wehling M; Eisen C; Christ M
    Mol Cell Endocrinol; 1992 Dec; 90(1):C5-9. PubMed ID: 1338726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renin-aldosterone system evaluation over four decades in an extended family with autosomal dominant pseudohypoaldosteronism due to a deletion in the NR3C2 gene.
    Hanukoglu A; Vargas-Poussou R; Landau Z; Yosovich K; Hureaux M; Zennaro MC
    J Steroid Biochem Mol Biol; 2020 Nov; 204():105755. PubMed ID: 33017655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autosomal-dominant pseudohypoaldosteronism type 1 in a Turkish family is associated with a novel nonsense mutation in the human mineralocorticoid receptor gene.
    Riepe FG; Krone N; Morlot M; Peter M; Sippell WG; Partsch CJ
    J Clin Endocrinol Metab; 2004 May; 89(5):2150-2. PubMed ID: 15126534
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pseudohypoaldosteronism: mineralocorticoid unresponsiveness syndrome.
    Jaruratanasirikul S; Janjindamai W
    J Med Assoc Thai; 2000 Aug; 83(8):948-52. PubMed ID: 10998851
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanisms of type I and type II pseudohypoaldosteronism.
    Furgeson SB; Linas S
    J Am Soc Nephrol; 2010 Nov; 21(11):1842-5. PubMed ID: 20829405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional polymorphisms in the mineralocorticoid receptor and amirolide-sensitive sodium channel genes in a patient with sporadic pseudohypoaldosteronism.
    Arai K; Nakagomi Y; Iketani M; Shimura Y; Amemiya S; Ohyama K; Shibasaki T
    Hum Genet; 2003 Jan; 112(1):91-7. PubMed ID: 12483305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism.
    Sartorato P; Khaldi Y; Lapeyraque AL; Armanini D; Kuhnle U; Salomon R; Caprio M; Viengchareun S; Lombès M; Zennaro MC
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):119-25. PubMed ID: 15134810
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1.
    Hubert EL; Teissier R; Fernandes-Rosa FL; Fay M; Rafestin-Oblin ME; Jeunemaitre X; Metz C; Escoubet B; Zennaro MC
    J Am Soc Nephrol; 2011 Nov; 22(11):1997-2003. PubMed ID: 21903996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism.
    Sartorato P; Lapeyraque AL; Armanini D; Kuhnle U; Khaldi Y; Salomon R; Abadie V; Di Battista E; Naselli A; Racine A; Bosio M; Caprio M; Poulet-Young V; Chabrolle JP; Niaudet P; De Gennes C; Lecornec MH; Poisson E; Fusco AM; Loli P; Lombès M; Zennaro MC
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2508-17. PubMed ID: 12788847
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reducing αENaC expression in the kidney connecting tubule induces pseudohypoaldosteronism type 1 symptoms during K+ loading.
    Poulsen SB; Praetorius J; Damkier HH; Miller L; Nelson RD; Hummler E; Christensen BM
    Am J Physiol Renal Physiol; 2016 Feb; 310(4):F300-10. PubMed ID: 26582762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel frameshift mutation in NR3C2 leads to decreased expression of mineralocorticoid receptor: a family with renal pseudohypoaldosteronism type 1.
    Kawashima Sonoyama Y; Tajima T; Fujimoto M; Hasegawa A; Miyahara N; Nishimura R; Hashida Y; Hayashi A; Hanaki K; Kanzaki S
    Endocr J; 2017 Jan; 64(1):83-90. PubMed ID: 27725360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pseudohypoaldosteronism: evaluation of type I receptors by radioreceptor assay and by antireceptor antibodies.
    Armanini D; Karbowiak I; Zennaro CM; Zovato S; Pratesi C; De Lazzari P; Krozowski Z; Kuhnle U
    Steroids; 1995 Jan; 60(1):161-3. PubMed ID: 7792805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.